BOOK
Evaluation of the Surgical Margin, An Issue of Oral and Maxillofacial Clinics of North America, E-Book
Joshua Lubek | Kelly Magliocca
(2017)
Additional Information
Book Details
Abstract
This issue of Oral and Maxillofacial Surgery Clinics of North America focuses on Evaluation of the Surgical Margin, and is edited by Drs. Joshua E. Lubek and Kelly Magliocca. Articles will include: Understanding the Surgical Margin: A Pathologist’s Perspective; Understanding the Surgical Margin: A Molecular Assessment; Margin Analysis: Squamous Cell Carcinoma of the Oral Cavity; Margin Analysis: Squamous Cell Carcinoma of the Oropharynx; Bone Margin Analysis: Segmental Versus Marginal Resection in Malignant Disease; Bone Margin Analysis for Benign Odontogenic Tumors; Bone Margin Analysis for Osteonecrosis and Osteomyelitis of the Jaws; Margin Analysis: Malignant Salivary Gland Neoplasms of the Head and Neck; Margin Analysis: Benign Salivary Gland Neoplasms of the Head and Neck; Margin Analysis: Cutaneous Malignancy of the Head and Neck; Margin Analysis: Sarcoma of the Head and Neck; Has Reconstruction Improved Tumor Surgery Outcomes?; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Evaluation of the SurgicalMargin\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Introduction | vii | ||
| Preface: Evaluation of the Surgical Margin: An Interdisciplinary Approach | vii | ||
| Understanding the Surgical Margin: A Molecular Assessment | vii | ||
| Margin Analysis: Squamous Cell Carcinoma of the Oral Cavity | vii | ||
| Margin Analysis: Squamous Cell Carcinoma of the Oropharynx | vii | ||
| Evaluation of the Bone Margin in Oral Squamous Cell Carcinoma | vii | ||
| Bone Margin Analysis for Benign Odontogenic Tumors | viii | ||
| Bone Margin Analysis for Osteonecrosis and Osteomyelitis of the Jaws | viii | ||
| Margin Analysis: Malignant Salivary Gland Neoplasms of the Head and Neck | viii | ||
| Margins for Benign Salivary Gland Neoplasms of the Head and Neck | viii | ||
| Margin Analysis: Cutaneous Malignancy of the Head and Neck | ix | ||
| Margin Analysis: Sarcoma of the Head and Neck | ix | ||
| Surgical Margins: The Perspective of Pathology | ix | ||
| Margin Analysis—Has Free Tissue Transfer Improved Oncologic Outcomes for Oral Squamous Cell Carcinoma? | ix | ||
| ORAL AND MAXILLOFACIAL SURGERY\rCLINICS OF NORTH AMERICA\r | x | ||
| FORTHCOMING ISSUES | x | ||
| November 2017 | x | ||
| February 2018 | x | ||
| May 2018 | x | ||
| RECENT ISSUES | x | ||
| May 2017 | x | ||
| February 2017 | x | ||
| November 2016 | x | ||
| Introduction | xi | ||
| Preface\r | xiii | ||
| Evaluation of the Surgical Margin: An Interdisciplinary Approach | xiii | ||
| Understanding the Surgical Margin | 245 | ||
| Key points | 245 | ||
| SURGICAL RESECTION OF HEAD AND NECK CANCERS | 245 | ||
| INCORPORATING MOLECULAR SURGICAL MARGINS IN HEAD AND NECK CANCER | 245 | ||
| UNDERSTANDING HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENCE | 246 | ||
| SURGICAL MARGIN MOLECULAR MARKERS | 247 | ||
| Genetic Events in the Head and Neck Squamous Cell Carcinoma Model of Progression as Molecular Surgical Markers | 247 | ||
| Methylation Patterns as a Molecular Surgical Margin Marker | 249 | ||
| Protein Expression as a Molecular Marker in Molecular Surgical Margin Analysis | 250 | ||
| FACTORS TO CONSIDER WHEN SELECTING MARGINS FOR ANALYSIS | 252 | ||
| LIMITATIONS OF MOLECULAR SURGICAL MARGINS | 253 | ||
| EMERGING RESEARCH AND FUTURE DIRECTIONS | 254 | ||
| REFERENCES | 255 | ||
| Margin Analysis | 259 | ||
| Key points | 259 | ||
| SURGICAL MARGIN SHRINKAGE | 261 | ||
| INTRAOPERATIVE FROZEN SECTIONS | 261 | ||
| FROZEN SECTIONS: DEFECT-DRIVEN VERSUS SPECIMEN-DRIVEN | 263 | ||
| THE USE OF BIOMARKERS IN EVALUATING THE SURGICAL MARGIN | 263 | ||
| MARGIN STATUS AND ADJUVANT THERAPY | 264 | ||
| REFERENCES | 265 | ||
| Margin Analysis | 269 | ||
| Key points | 269 | ||
| INTRODUCTION | 269 | ||
| SURGICAL TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 270 | ||
| Transoral Laser Microsurgery | 270 | ||
| Transoral Robotic Surgery | 270 | ||
| BIOLOGICAL DIFFERENCE OF HUMAN PAPILLOMA VIRUS–POSITIVE AND NEGATIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 271 | ||
| OUTCOMES OF SURGICAL TREATMENT REGARDING MARGINS | 273 | ||
| FUTURE DIRECTIONS | 276 | ||
| Optical Fluorescence Imaging | 276 | ||
| Narrow Band Imaging | 277 | ||
| Intraoperative Ultrasound | 277 | ||
| Molecular Markers of Margins | 277 | ||
| SUMMARY | 278 | ||
| REFERENCES | 278 | ||
| Evaluation of the Bone Margin in Oral Squamous Cell Carcinoma | 281 | ||
| Key points | 281 | ||
| PATTERNS OF BONE INVASION AND SPREAD | 281 | ||
| PREDICTORS OF MAXILLARY AND MANDIBULAR BONE INVOLVEMENT | 282 | ||
| IMAGING TECHNIQUES | 283 | ||
| MARGINAL VERSUS SEGMENTAL RESECTION | 285 | ||
| Rim or Sagittal Resection | 285 | ||
| Does marginal resection affect outcome in the face of bone invasion identified on postoperative pathology? | 286 | ||
| CLINICAL AND HISTOPATHOLOGIC INTRAOPERATIVE EVALUATION OF THE BONE MARGIN | 286 | ||
| SUMMARY | 290 | ||
| REFERENCES | 290 | ||
| Bone Margin Analysis for Benign Odontogenic Tumors | 293 | ||
| Key points | 293 | ||
| INTRODUCTION | 293 | ||
| Ameloblastoma | 294 | ||
| Odontogenic Keratocyst and Keratocystic Odontogenic Tumor | 296 | ||
| Odontogenic Myxoma | 297 | ||
| Calcifying Epithelial Odontogenic Tumor or Pindborg Tumor | 298 | ||
| Adenomatoid Odontogenic Tumor | 298 | ||
| SUMMARY | 299 | ||
| REFERENCES | 299 | ||
| Bone Margin Analysis for Osteonecrosis and Osteomyelitis of the Jaws | 301 | ||
| Key points | 301 | ||
| INTRODUCTION | 301 | ||
| OSTEOMYELITIS | 301 | ||
| MEDICATION-RELATED OSTEONECROSIS | 304 | ||
| OSTEORADIONECROSIS | 307 | ||
| SUMMARY | 310 | ||
| REFERENCES | 311 | ||
| Margin Analysis | 315 | ||
| Key points | 315 | ||
| INTRODUCTION | 315 | ||
| SITE-SPECIFIC CONSIDERATIONS | 316 | ||
| LOW-GRADE SALIVARY MALIGNANCIES | 316 | ||
| POTENTIALLY AGGRESSIVE SALIVARY MALIGNANCIES | 318 | ||
| HIGH-GRADE MALIGNANCIES | 320 | ||
| CENTRAL (INTRAOSSEOUS) SALIVARY GLAND CARCINOMA | 322 | ||
| SUMMARY | 322 | ||
| REFERENCES | 322 | ||
| Margins for Benign Salivary Gland Neoplasms of the Head and Neck | 325 | ||
| Key points | 325 | ||
| INTRODUCTION | 325 | ||
| BENIGN PAROTID GLAND TUMORS | 326 | ||
| Superficial Parotidectomy | 327 | ||
| Partial Superficial Parotidectomy | 330 | ||
| Extracapsular Dissection | 332 | ||
| BENIGN SUBMANDIBULAR GLAND TUMORS | 334 | ||
| BENIGN MINOR SALIVARY GLAND TUMORS | 335 | ||
| OPERATING SURGEON AND SURGICAL PATHOLOGIST INTERACTIONS: INTRAOPERATIVE CONSULTATIONS AND FROZEN SECTIONS | 336 | ||
| SUMMARY | 338 | ||
| REFERENCES | 339 | ||
| Margin Analysis | 341 | ||
| Key points | 341 | ||
| INTRODUCTION | 341 | ||
| BASAL CELL CARCINOMA | 341 | ||
| Epidemiology | 341 | ||
| Pathogenesis | 342 | ||
| Preoperative and Risk Assessment | 342 | ||
| Management | 342 | ||
| Appropriate Surgical Margin | 343 | ||
| Response to a Positive Margin | 343 | ||
| SQUAMOUS CELL CARCINOMA | 343 | ||
| Epidemiology | 343 | ||
| Pathogenesis | 344 | ||
| Preoperative and Risk Assessment | 344 | ||
| Management | 344 | ||
| Appropriate Surgical Margin | 344 | ||
| Response to a Positive Margin | 345 | ||
| FROZEN SECTION ANALYSIS FOR BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA | 345 | ||
| CUTANEOUS MALIGNANT MELANOMA | 348 | ||
| Epidemiology | 348 | ||
| Pathogenesis | 348 | ||
| Preoperative and Risk Assessment | 348 | ||
| Management | 349 | ||
| Appropriate Margin | 349 | ||
| FROZEN SECTIONS ANALYSIS FOR CUTANEOUS MALIGNANT MELANOMA | 350 | ||
| REFERENCES | 351 | ||
| Margin Analysis | 355 | ||
| Key points | 355 | ||
| INTRODUCTION | 355 | ||
| HISTOLOGIC TYPES AND CLASSIFICATION OF HEAD AND NECK SARCOMAS | 355 | ||
| PATHOGENESIS AND PREDISPOSING FACTORS IN HEAD AND NECK SARCOMAS | 356 | ||
| GENETIC PREDISPOSITION | 356 | ||
| Li-Fraumeni Syndrome | 356 | ||
| Retinoblastoma Gene | 356 | ||
| Neurofibromatosis Type-I (Mutations in NF1 Gene) | 356 | ||
| GENERAL PRINCIPLES IN DIAGNOSIS AND TREATMENT OF HEAD AND NECK SARCOMAS | 356 | ||
| Diagnosis | 356 | ||
| Surgical Treatment | 356 | ||
| Adjuvant Chemotherapy and Radiotherapy | 357 | ||
| Variables with Possible Prognostic Impact in Head and Neck Sarcoma | 357 | ||
| RESECTION MARGINS AFFECT RECURRENCE RATE AND TREATMENT MODALITIES IN SELECTED HEAD AND NECK SARCOMA | 358 | ||
| Osteosarcoma | 358 | ||
| Management of head and neck osteosarcoma | 358 | ||
| Chondrosarcoma | 359 | ||
| Rhabdomyosarcoma | 360 | ||
| Surgical Margins | 367 | ||
| Key points | 367 | ||
| OVERVIEW | 367 | ||
| THE HANDOFF ORIENTATION | 367 | ||
| DEFINITIONS OF MUCOSAL, SKIN, SOFT TISSUE, NERVE, AND BONE MARGINS | 369 | ||
| ARE ALL SURGICAL MARGINS EQUALLY IMPORTANT? | 371 | ||
| POSTREMOVAL SPECIMEN CHANGES | 372 | ||
| INDETERMINATE RESECTION MARGIN STATUS | 373 | ||
| SUMMARY | 374 | ||
| ACKNOWLEDGMENTS | 374 | ||
| REFERENCES | 374 | ||
| Margin Analysis—Has Free Tissue Transfer Improved Oncologic Outcomes for Oral Squamous Cell Carcinoma? | 377 | ||
| Key points | 377 | ||
| REFERENCES | 380 |